Tumor Growth and Body Weight Findings from the Colo205-e396 Study
The Colo205-e396 preclinical study evaluated SAC-SG in a mouse model of colorectal cancer. According to the study report dated January 20, 2025, the study was conducted by Charles River Discovery Services.
SAC-SG, identified as YYM1 in the response summary, was administered orally at 150 mg/kg twice daily over a 21-day treatment period. The report compared tumor volume and body weight outcomes between the treatment and vehicle control groups, with eight animals in each group.
At Day 21, the reported median tumor volume was lower in the SAC-SG group than in the vehicle group, corresponding to a reported tumor growth inhibition of 31.4%. The treatment group also showed a partial recovery in body weight after reaching its lowest point around Day 15.
- The study evaluated oral SAC-SG at 150 mg/kg twice daily in a preclinical colorectal cancer model.
- Day 21 median tumor volume was 498 mm³ in the SAC-SG group and 726 mm³ in the vehicle control group.
- The response summary reported 31.4% tumor growth inhibition.
- Mean body weight in the SAC-SG group reached its lowest point around Day 15 and subsequently partially recovered.
- No treatment-related deaths were recorded in either group in the response summary.
- The supplied report does not establish a survival benefit, a confirmed mechanism of action, or clinical efficacy in humans.
Study Design and Treatment Regimen
The study compared vehicle treatment with SAC-SG in the Colo205-e396 colorectal cancer model. The response table lists eight animals per group and identifies the test agent as YYM1.
SAC-SG was administered orally at 150 mg/kg twice daily. The tabulated schedule specifies twice-daily administration at a 10-hour interval for 21 days, followed by a morning administration on Day 22. The response summary presents tumor volume results for Day 21.
Tumor volume and normalized body weight were monitored during the study. These measurements provide information about tumor growth and changes in general condition under the tested experimental regimen.
Lower Tumor Volume at Day 21
The Day 21 response summary reports a median tumor volume of 726 mm³ in the vehicle group and 498 mm³ in the SAC-SG group. The corresponding reported tumor growth inhibition was 31.4%.
The tumor volume graph shows that tumors grew in both groups during the earlier part of the study. During the later observation period, the SAC-SG group showed a flatter mean tumor volume trajectory than the vehicle group.
These findings indicate reduced tumor growth relative to the control group under the tested conditions. They should not be interpreted as complete tumor regression or elimination of disease.
| Reported Measure | Vehicle Control | SAC-SG / YYM1 |
|---|---|---|
| Animals per group | 8 | 8 |
| Test-agent dose | Vehicle only | 150 mg/kg, orally, twice daily |
| Day 21 median tumor volume | 726 mm³ | 498 mm³ |
| Tumor growth inhibition | Reference group | 31.4% |
| Lowest mean body weight change | −3.6% on Day 8 | −12.2% on Day 15 |
| Treatment-related deaths | 0 | 0 |
Values are taken from the supplied response summary. Body weight nadir denotes the lowest group mean body weight relative to baseline; it is not a measure of weight recovery.
Interpreting the Body Weight Findings
The body weight graph shows a larger decline in the SAC-SG group than in the vehicle group. The reported nadir was −12.2% on Day 15 for SAC-SG, compared with −3.6% on Day 8 for the vehicle group.
After Day 15, mean body weight in the SAC-SG group increased toward Day 22 but remained below baseline. This pattern is best described as partial recovery following an initial decline.
These observations do not establish reversal of cancer-associated cachexia or an improvement in overall systemic health. The cause of the initial weight loss was not established by the information provided.
Tolerability and Survival Observations
The response summary records no treatment-related deaths in either group. However, the observed body weight decline in the SAC-SG group remains relevant when assessing tolerability.
The supplied report does not provide a comprehensive toxicology assessment. An absence of treatment-related deaths alone cannot establish an absence of adverse effects or a favorable clinical safety profile.
The report also discusses a possible survival advantage based on projected tumor burden. This is a projection rather than a demonstrated survival outcome; a survival benefit cannot be concluded from the supplied results.
Proposed Mechanisms and Further Investigation
The report proposes that SAC-SG may influence cancer cell calcium homeostasis and oxidative stress. It also discusses possible involvement of glucose transporters and changes in the tumor microenvironment.
These mechanisms are presented as proposed explanations. The supplied report does not include direct experimental measurements establishing glucose transporter-mediated uptake, intracellular calcium changes, free radical production, or effects on lactate and ammonia metabolism.
Additional mechanistic experiments would be needed to determine whether these processes contribute to the observed tumor growth findings.
Research Significance and Limitations
The lower Day 21 tumor volume and reported 31.4% tumor growth inhibition provide a preliminary basis for further investigation of SAC-SG in this experimental model.
Although the narrative describes the tumor effect as significant, the statistical significance field in the supplied response table is blank, and no corresponding p-values or statistical methods are provided. Statistical significance therefore cannot be independently assessed from this summary.
Further work would be needed to assess reproducibility, dose response, the cause of the body weight changes, comprehensive safety, and survival outcomes. These preclinical findings do not establish SAC-SG as an effective treatment for colorectal cancer in humans.
